Clancy, Lei­bowitz to step down from key fed­eral posts

Modern Healthcare - - LATE NEWS - — Mau­reen McKinney and Joe Carl­son

Two fed­eral of­fi­cials with sig­nif­i­cant in­flu­ence in health­care are leav­ing the Obama ad­min­is­tra­tion. Dr. Carolyn Clancy, who has led HHS’ Agency for Health­care Re­search and Qual­ity for nearly a decade, will leave her post “in the coming months,” ac­cord­ing to a memo to em­ploy­ees from HHS Sec­re­tary Kath­leen Se­be­lius. Clancy, 59, an in­ternist, was named AHRQ’s di­rec­tor in Fe­bru­ary 2003 and was reap­pointed in Oc­to­ber 2009. She joined AHRQ in 1990 and pre­vi­ously served as di­rec­tor of its Cen­ter for Out­comes and Ef­fec­tive­ness Re­search. Se­be­lius praised Clancy for rais­ing AHRQ’s vis­i­bil­ity and spear­head­ing ini­tia­tives fo­cused on health­care dis­par­i­ties and pa­tient safety. The same day Clancy’s de­par­ture was re­vealed, Fed­eral Trade Com­mis­sion Chair­man Jon Lei­bowitz said he would step down Feb. 15. Lei­bowitz, 54, has served as one of five com­mis­sion­ers on the FTC since 2004 and chair­man since March 2009. Un­der his lead­er­ship, the FTC brought law­suits to stop hospi­tal merg­ers in Ge­or­gia, Illi­nois, Ohio and Penn­syl­va­nia and, in Ne­vada, brought its first-ever ac­tion to protest a physi­cian-prac­tice ac­qui­si­tion. The com­mis­sion has also waged a high-pro­file bat­tle against brand­name drug man­u­fac­tur­ers who pay po­ten­tial com­peti­tors not to mar­ket generic equiv­a­lent drugs. “Health­care has been a pri­or­ity here for many years,” FTC Com­pe­ti­tion Bureau Di­rec­tor Richard Fe­in­stein said. “I think it’s ap­pro­pri­ate that it is—it af­fects ev­ery­body. And I would think it will re­main a pri­or­ity.”

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.